HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China. [electronic resource]
Producer: 20140930Description: 845 p. digitalISSN:- 1559-131X
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- China
- Cyclophosphamide -- administration & dosage
- Doxorubicin -- administration & dosage
- Female
- Follow-Up Studies
- Hepatitis B -- complications
- Hepatitis B Surface Antigens -- metabolism
- Hepatitis B virus -- genetics
- Humans
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Neoplasm Staging
- Prednisone -- administration & dosage
- Prognosis
- Retrospective Studies
- Rituximab
- Survival Rate
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.